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Ovarian cancer is the most common type of gynecologic malignancy. Despite advances in surgery and chemotherapy, the survival
rate is still low since most ovarian cancers relapse and become drug-resistant. Chemokines are small chemoattractant peptides
mainly involved in the immune responses. More recently, chemokines were also demonstrated to regulate extra-immunological
functions. It was shown that the chemokine network plays crucial functions in the tumorigenesis in several tissues. In particular
the imbalanced or aberrant expression of CXCL12 and its receptor CXCR4 strongly aﬀects cancer cell proliferation, recruitment
of immunosuppressive cells, neovascularization, and metastasization. In the last years, several molecules able to target CXCR4
or CXCL12 have been developed to interfere with tumor growth, including pharmacological inhibitors, antagonists, and speciﬁc
antibodies. This chemokine ligand/receptor pair was also proposed to represent an innovative therapeutic target for the treatment
of ovarian cancer. Thus, a thorough understanding of ovarian cancer biology, and how chemokines may control these diﬀerent
biological activities might lead to the development of more eﬀective therapies. This paper will focus on the current biology of
CXCL12/CXCR4 axis in the context of understanding their potential role in ovarian cancer development.
1.Introduction
Chemokines are small secreted cytokines, primarily involved
in the regulation of the motility of hematopoietic cells (cells
of the immune system) in their speciﬁc homing to lymphoid
organs in normal hematopoiesis and during inﬂammation
[1], through the activation of speciﬁc G-protein coupled
receptors [2].
To date 53 human chemokines and 23 receptors have
been cloned and characterized.
Chemokines display high structural homology and over-
lapping functions and often bind more than one receptor.
In general, ligand binding causes chemokine receptor acti-
vation, hallmarked by the phosphorylation of C-terminal
serine/threonine residues that, in turn, drives dissociation of
heterotrimeric G-proteins into α and βγ subunits, inhibition
of adenylyl cyclase activity, increased generation of inositol
trisphosphate, intracellular calcium release, and the activa-
tion of phosphatidyl inositol 3 kinase (PI3K)/Akt cascade
and Ras/MAP kinase signalling [3].
Chemokines are divided into subfamilies by struc-
tural and functional criteria. Structurally, chemokines are
classiﬁed into four groups (C, CC, CXC, and CX3C)
according to the number and location of the conserved
cysteine residues in the primary structure of these molecules
(Figure 1). The “C” group of chemokines (containing only
two cysteines) consists of two molecules (XCL), namely,
XCL1/lymphotactin and XCL2/SCM-1β, both binding the
receptor XCR1. Lymphotactin, coded on human chro-
mosome 1, attracts lymphocytes but not monocytes or
neutrophils.
Human “CC” chemokines (structurally characterized by
four cysteines) includes 28 members, called CCL1-28 that
bind at least 10 receptors (CCR1-10). CC chemokine targets
include monocytes, T cells, dendritic cells, eosinophils, and
basophils. Representative CC chemokines are CCL2 (also
called monocyte chemotactic protein, MCP-1), CCL3 and
CCL4 (macrophage inﬂammatory protein MIP-1α and MIP-
1β), CCL5 (RANTES), and CCL11 (eotaxin).2 Journal of Oncology
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Figure 1: Chemokinesubfamiliesclassiﬁcation.Theﬁrstcysteine (C)
in the sequence forms a covalent bond with the third, the second
and the fourth cysteines also form a disulﬁde bond to create the
tertiary structure characteristic of chemokines. In the CC subfamily
the ﬁrst two cysteines are adjacent to each other, in the CXC group
there is one amino acid between the ﬁrst two cysteines, and in the
CX3C group there are three amino acids between cysteines.
The “CXC” group (in which one amino acid is present
between the ﬁrst two cysteines) includes 21 ligands (CXCL1-
21) mostly encoded on human chromosome 4. CXC
chemokinesbindatleast7receptors(CXCR1-7)andmediate
neutrophil chemotaxis. The CXC group can be divided
into two main categories based on the presence of the
tripeptide Glu-Leu-Arg (ELR) before the CXC motif (N-
terminal domain). Representative CXC chemokines include
CXCL8/IL-8, among the ELR-containing peptides and
CXCL9/monokine-induced by IFN-γ (MIG), CXCL10/IFN-
γ inducible protein-10 (IP-10), and CXCL12/stromal cell-
derived factor-1 (SDF1) as ELR negative molecules.
Lastly, the “CX3C” chemokines (three amino acids
between the ﬁrst two cysteines) are, to date, represented
by a single peptide, namely, CX3CL1/fractalkine, which is
encoded on human chromosome 16, binds the CX3CR1
receptor and regulates T cell traﬃcking and adhesion [4].
Functionally, chemokines, released upon inﬂamma-
tory stimuli that induce leukocyte recruitment to dam-
aged/infected sites, are considered as “inﬂammatory” [5]
while chemokines that induce migration of leukocytes to
lymphoid organs are considered “homeostatic” and are
usually constitutively secreted by stromal cells expressed at
these sites [6]. Homeostatic chemokines, such as CXCL12,
coordinate cell traﬃcking and homing, which is essential
during development and for homeostasis and function of the
immune system.
More recently, several extra-immunological functions
were discovered for most of the components of the
chemokine sub-families (for review see [7]). In particular, it
was demonstrated that chemokines are major players during
embryonic development, when their role as chemotactic
mediators contribute to cell migration in the diﬀerent
body districts. Moreover, in the adult, chemokines play a
relevant function in the central nervous system (CNS) where
both ligands and receptors are expressed [8, 9]. At CNS
level, chemokines control, among other functions, pain,
alimentary behavior and glial responses to injuries [10–12].
2. Chemokines inCancer
In cancer, genetic changes that accumulate in transformed
cells are dependent on microenvironmental factors and
control the development of the malignant process. In the
past few years, a major role has been assigned to chemokines
and their receptors as molecules that aﬀect neoplastic
development and progression.
Many chemokine/receptor pairs are expressed in tumors,
not only by cancer cells but also by cells of the tumor
microenvironment,includingcellsofthestroma(endothelial
cells, ﬁbroblasts) and leukocytes, thus contributing to the
cross-talk between the tumor and its microenvironment to
control tumor growth and progression [13].
In the malignancy context, chemokines play diverse
eﬀects, most of them deriving from their ability to induce
cell migration. The ability of chemokines to enhance the
motility of leukocytes, endothelial cells, and/or tumor cells
is a key factor in determining the cancer establishment and
progression. Depending on their speciﬁc expression pattern
on target cells, on tumor type and on tumor microenviron-
ment factors, several chemokines support malignancy, while
others can at times inhibit this process [14].
Theextensiveresearchthatwasthusfarperformedonthe
roles of chemokines in cancer indicates that these molecules
aﬀect tumors mainly acting at four levels: (a) determine
the extent and type of leukocyte inﬁltrates; (b) promote
angiogenesis; (c) control site-speciﬁc metastasization; (d)
aﬀect tumor cells proliferation [15, 16].
The immune response induced by malignancy is clearly
evident since many solid tumors are highly populated by
host leukocytes that have migrated into the tumor from the
systemic circulation.
In tumors, leukocyte inﬁltrates may have either anti-
cancer or cancer-promoting eﬀects, depending on their
type, their activity, and their modes of interaction with the
tumor cells. In line with their classiﬁcation as leukocyte
chemoattractants, chemokines are released by tumor cells or
by cells of their microenvironment and are able to induce
the recruitment of diﬀerent hematopoietic cell subtypes to
tumors (T lymphocytes, macrophages, natural killer (NK)
cells, neutrophils, eosinophils, and B cells). In particular,
among CXC chemokines, CXCL9, CXCL10, and CXCL11 are
induced by interferon γ (IFNγ) and are typical chemoat-
tractants of NK cells [15]. Accordingly, overexpression of
these chemokines by diﬀerent experimental means leads to
limitations in cancer development, associated with elevation
in cytotoxic responses and with the creation of long-term
antitumor immunity. These chemokines have additional
antitumor activities but at the same time they may exert
tumorigenic functions when acting directly on the tumor
cells [17].
On the other hand, some chemokines may induce proan-
giogenic eﬀects, leading to highly neovascularized tumors
and increased metastatic spread. A large number of studies
now clearly indicate that chemokines, mainly belonging
to the CXC and CC subgroups, are important regulators
of tumor angiogenesis. However, also on this parameter,
opposite ﬁnal eﬀects may occur; some chemokines supportJournal of Oncology 3
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Figure 2: Signaling pathways downstream CXCR4 receptor activation. Upon CXCL12 binding the G protein complex dissociates into α and
βγ subunits that trigger parallel signal transduction cascades culminating in tumor cell proliferation, migration, or survival. AC: adenylyl
cyclase;ER:endoplasmicreticulum;PLC:phospholipaseC;PI3K:phosphoinositide3-kinase;PKB/Akt:proteinkinaseB;PKC:proteinkinase
C; PYK2: proline-rich tyrosine kinase 2; ERK1/2: extracellular regulated kinase.
the formation of new blood vessels, while others are angio-
static.
Angiogenic CXC chemokines promote the migration
and proliferation of endothelial cells. Accordingly, they were
shown to be potent tumor-supporting factors in a large
varietyoftumortypes.Forexample,CXCL8actsonendothe-
lial cells mainly via their high aﬃnity CXCR2 receptor
[18]. Conversely, other CXC chemokines, including CXCL4,
CXCL9,CXCL10,andCXCL11arepotentangiostaticfactors.
Their activity, via the CXCR3, receptor inhibits the neovas-
cularization induced by powerful angiogenic factors. This
activity of CXC chemokines, altogether with their ability to
recruit antitumoral immune cells, led to the hypothesis of a
function for these peptides as potential antitumoral factors.
Incontrast,CXCL12,anotherrelevantmemberofthisgroup,
promotes tumor neoangiogenesis under speciﬁc conditions,
thus being regarded as one of the most powerful pro-
malignancy factors [19]. Many chemokines sustain cancer
cell proliferation and survival, through an interaction with
receptors expressed by the tumor cells. Such an activity was
reported for CXCL8 that acts as an autocrine growth factor
forhumanovariancancerHey-A8cellline[20].Moreover,in
vivostudiesshowedthatCXCL8-overexpressingHey-A8cells
are able to increase tumor cell growth, microvessel density,
and the tumorigenic rate [20].
The chemokine CXCL12 also exerts a direct eﬀect on
tumor cell proliferation and survival in a high variety of
tumors. In fact, altogether with its receptor CXCR4, CXCL12
constitutes the chemokine/receptor axis that attracted the
greatest interest in oncology. This receptor-ligand system
was reported to be overexpressed in several cancer types
including acute and chronic leukemias [21] and solid
tumors such as breast [22], colon [23], prostate [24], and
ovarian cancers [25], glioblastomas [26, 27], melanomas
[28], pituitary adenomas [29], and meningiomas [30, 31].
Physiologically, the CXCR4/CXCL12 axis is involved in
migration of embryonic cells participating to the devel-
opment of the central nervous system, bone marrow, and
heart [32, 33]. Although for many years the interaction
between CXCR4 and CXCL12 was thought to be unique,
more recently, it was reported that CXCL12 binds also to
another receptor, named CXCR7 [34]. CXCR7 is expressed
in several cell types, including endothelial cells, T and B cells,
dendritic cells, chondrocytes, endometrial stromal cells. The
interaction of CXCL12 with CXCR4 mainly aﬀects chemo-
taxis, while the binding to CXCR7 mediates proliferation in
tumor cells [35]. Thus, CXCL12 can modulate the migration
capacity of tumor cells and CXCR7 can enhance tumor
growth.
Chemokines interacting to speciﬁc G protein coupled
receptors (GPCRs) activate several signalling pathways in
both normal and cancer cells. In normal cells, upon activa-
tion, CXCR4 dimerizes and transduces several intracellular
signals (Figure 2). Most of them are PTX-sensitive and
therefore dependent on activation of Gi/Go proteins, includ-
ing Gα and Gβγ-mediated signals. Gαι activation implies
the inhibition of adenylyl cyclase (AC) function, thereby
determining a decrease in the cytosolic concentration of
cyclic AMP (cAMP), and leading to the inhibition of
protein kinase A (PKA). Gαq transduces the CXCR4 signals
through the activation of phospholipase Cβ (PLC) which
increases inositol triphosphate and intracellular calcium
levels. Chemokine signalling activated by Gβγ induces a
direct activation of PI3 kinase (PI3K), a survival regulator4 Journal of Oncology
acting on eﬀectors of apoptosis [36]. PI3K activation is
often detected in cancer as mediator of the increased
survival of the tumor cells. Importantly, beside survival,
chemokines in general, and CXCL12 in particular, are also
powerful activators of the MAP kinase (ERK1/2) cascade, the
most studied proliferative mechanism responsible of tumor
growth[30,36].Interestingly,ERK1/2activationmayinvolve
either the classical Ras/Raf/MEK pathway or the activation
of the cytosolic, Ca++-dependent tyrosine kinase Pyk2 [11].
However, in pituitary adenoma cell lines, CXCR4-induced
activation of the calcium-dependent protein kinase Pyk2
was involved in a proliferative response independent by
ERK1/2andinvolvinglargeconductanceCa2+-dependentK+
channels [37, 38]. Thus, the intracellular signaling involved
in CXCL12 tumor cell proliferation is extremely dependent
on the cell type analyzed.
More recently, several studies proposed that CXCR4-
dependent activation of ERK1/2 was mediated by trans-
activation of tyrosine kinase receptors. Cross-talk between
growth factor and G protein-coupled receptors is now
b e l i ev e dt op l a ya ni m p o rt a n tr o l ei nb o t hn o rm a la n dt u m o r
responses. In particular, the transactivation of epidermal
growth factor receptor (EGFR) and the activation of its
downstream signaling pathways are critical for the mitogenic
activity of diﬀerent GPCR ligands, including chemokines.
In the ovarian cancer cell line SKOV-3, CXCL8/IL-8 was
shown to induce transient phosphorylation of EGFR and
its association with the adaptor molecules Shc and Grb2,
suggests an important cross-talk between chemokine and
growth factor pathways [39]. In three other ovarian cancer
cell lines (OC 314, OC 315, OC 316), it was demonstrated
that CXCL12/CXCR4 interaction induces a dose-dependent
cell proliferation through ERK1/2 and Akt activation that
was dependent on EGFR phosphorylation caused by a mech-
anism involving the activity of the cytosolic tyrosine kinase
c-Src [40]. Thus, a “cross-talk” between CXCL12/CXCR4
and EGFR intracellular pathways may link signals of cell
migration and proliferation in ovarian cancer. A similar
mechanism was also demonstrated in breast cancer cell lines,
showing that estrogen-dependent proliferation involves the
synthesis of CXCL12 (identiﬁed as estradiol-dependent
gene), that causes an autocrine stimulation of CXCR4 and
the subsequent activation of c-Src that, in turn, induces a
ligand-independent activation of EGFR and ERK1/2 phos-
phorylation [41]. The transactivation of HER2/neu through
CXCL12 stimulation of CXCR4 and Src activation cells was
also demonstrated, in breast and prostate cancers [41–43].
3. Chemokines, Tumor-Speciﬁc Immune
Responses, and Tumor Microenvironment
The interaction of chemokines, their receptors, growth
factors, inﬂammatory with cancer cells forms a complex
network at the tumor site, responsible for the overall pro-
gression or rejection of the tumor. In particular, chemokines
play an essential role in coordinating the function of the
immune system participating either in several steps of the
antitumor immunity or in the regulation of the release of
several mediators able to activate proangiogenic stimuli, and
thus supporting tumor development.
In fact, on one hand, chronic inﬂammation is often
associated with cancer development [44] with an inﬂam-
matory component detectable also in the microenviron-
ment of tumors non epidemiologically related to inﬂam-
mation [45]. Moreover, several chemokines (mainly of the
CXC/ELR+ family) are involved in regulation and recruit-
ment of multiple cell types within tumor microenvironment,
often possessing neoangiogenetic activity (Figure 3). Thus,
chemokines may exert not only a direct eﬀect on tumor
cells but may control tumor growth also through the
activation of their speciﬁc receptors expressed in a large
number of stromal (ﬁbroblasts and endothelial cells) and
inﬂammatory cells. Importantly these cells also secrete a
variety of chemokines, which regulate the migration of
inﬁltrating macrophages, lymphocytes, dendritic cells, and
neutrophils in response to a chemokine gradient [13].
On the other hand, the activity of severalchemokine may
be detrimental for tumor growth causing the recruitment
in tumor microenvironment cytotoxic T lymphocytes and
NK cells responsible of the immunosurveillance against
transformed cells (Figure 3).
Among CXC-chemokines, CXCL12 is known to regulate
the local immune response and is a potent chemoattractant
for T cells, pre-B lymphocytes, and dendritic cells and its
receptor CXCR4 is expressed by T lymphocytes, monocytes,
neutrophils, and endothelial cells. This chemokine produced
by diﬀerent cell types in the tumor microenvironment mod-
ulatestheactivityofimmunosuppressivecells(macrophages,
neutrophils, T regulatory cells) contributing to tumor pro-
gression.
The molecular pathways activated in tumor cells that
control cancer-related immunity include transcription fac-
tors, such as nuclear factor-κB( N F - κB), hypoxia inducible
factor α (HIF1α), and signal transducer and activator of
transcription 3 (STAT3), which, in turn, control the pro-
duction of other chemokines and inﬂammatory mediators
(prostaglandins, cytokines). Altogether these factors trigger
the recruitment of activated inﬂammatory cells generating
the cancer-related inﬂammatory microenvironment. For
example, tumor-associated leukocytes represent a source
of growth factors, acting on tumor cells, and angiogenic
factors.
This dual role of chemokines in tumor development, to
either eliminate malignant cells or escape the host immune
control, was demonstrated in several tumor types [46]. For
example, in melanoma, while chemokines contribute to the
recruitment of CD8+ T lymphocytes expressing CXCR3 that
inﬁltrate the tumor leading to the improvement of patient
survival [22], the lack of critical chemokines (CCL2, CCL3,
CCL4,CCL5,CXCL9,andCXCL10)inmelanomametastases
may block the migration of activated T cells, which in turn
could limit the eﬀectiveness of antitumor immunity [47].
On the other hand, the aberrant expression of chemokines
in tumors induces immunosuppression and favors tumor
growth as shown in hepatocellular carcinoma, where high
levels of CXCL9 and CXL10 have been associated with
inhibition of CXCR3 expression by CD8+ T limphocytes,Journal of Oncology 5
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Figure 3: Role of chemokines in the tumor-speciﬁc immune response. The type and the amount of the chemokines secreted by tumor and
inﬂammatory cells determine the extent and the eﬀect of immune response leading to antitumor cytotoxic response, limited inﬂammatory,
and vascular activation or potentiating tumor cell proliferation and neoangiogenesis.
reductionofT-celltumorinﬁltrationandcytotoxicfunctions
and tumor growth [48].
Another mechanism by which certain tumors evade
the immune system is through the chemorepulsive activity
of high levels of CXCL12. CXCL12 at low concentration
(<10nM) acts as a T cell chemoattractant [49], while higher
concentrations of the chemokine can repel T cells in vitro
andinvivoviaaCXCR4receptor-mediatedmechanism[50].
In conclusion, according to which chemokines are
released, completely opposite events may occur; abundant
production of proinﬂammatory chemokines (i.e., ELR+
CXC-chemokines) can lead to a strong inﬂammatory
response that potentiates angiogenesis, thus favoring a rapid
neoplastic growth. Alternatively, high levels of monocytes
and/or neutrophil inﬁltration, for example, in response
to ELR- chemokines, can be associated with angiostasis,
cytotoxicity, and possible tumor regression [19]( Figure 3).
On the basis of these evidences, the characterization
of the diﬀerent chemokine networks in various types of
cancer cells may foster better knowledge for understanding
the immune-related mechanisms of cancer development and
application in cancer immunotherapy.
4.OvarianCancer
Ovarian cancer causes more deaths than any other cancer of
the female reproductive system, representing the world sixth
most commonly diagnosed neoplasia among women [51].
Despite the high incidence and mortality rates, the etiology
of this disease is poorly understood. Age and family history
for the disease represent established risk factors for ovarian
cancer; other possible risk factors include postmenopausal
hormone-replacement therapy and lifestyle factors such as
cigarette smoking and alcohol consumption. However, in
many cases, the causes of ovarian cancer are yet to be
identiﬁed.
The progression of these tumors within the peritoneal
cavity results in late diagnosis and high mortality rate.
Indeed,themajorityofpatientsarediagnosed withadvanced
disease and treated with surgery and postoperative cis-
platinum- and taxane-based chemotherapy [52]. Moreover,
several patients exhibit primary resistance to chemotherapy
and approximately 70% achieve remission that is generally
not durable, with an overall 5-year survival rate of 20–30%
[53].6 Journal of Oncology
Ovarian cancers are histologically diverse: about 80%
originatesintheepithelium(epithelialovariancancer,EOC);
the remaining 20% arise from other cell types (germ cell,
sex cord-stromal, and mixed cell tumors) or are metastases
to the ovary (most commonly, from the breast or gastro-
intestinal tract tumors). EOC includes four histotypes
(serous, mucinous, clear cell, and endometrioid) diﬀering
for epidemiologic, genetic changes, tumor markers, and
response to therapy. The molecular events leading to the
development of EOC are not yet clear, although if genetic
and epigenetic alterations have commonly been observed.
One of the most frequent genetic changes (about 70%
of cases) is the mutation or loss of TP53 function but,
despite the great number of studies, its correlation with
chemoresistance and prognostic impact are not yet fully
proved [54]. Loss of heterozigosity and mutations BRCA1
and BRCA2 leading to inactivation of other genes, has
been described in familial ovarian cancers [55]. Mutations,
ampliﬁcation, and overexpression of well-known oncogenes,
such as PI3K subunit-α, FGF1, MYC, EGFR, KRAS, HER2,
and AKT2, have been also associated with ovarian cancer
[56].
The diﬀerent subtypes of ovarian cancer could be further
subclassiﬁed according to tumor cell type grade, taking into
account the diﬀerent molecular characteristics: high grade
serous cancers typically contain BRCA1 and TP53 mutations
(up to 80%); low grade serous carcinomas often have
mutations in the KRAS and BRAF genes (>60%), and low-
grade endometrioid cancers are associated with mutations
in the beta-catenin gene, CTNNB1, PTEN, and PI3CA and
mucinous carcinomas frequently have mutations in KRAS
and TP53. This subclassiﬁcation of ovarian cancers is essen-
tial because diﬀerent subtypes of ovarian cancer respond
diﬀerently to treatment and have diﬀerent prognoses
[57].
Some of the genes involved in ovarian cancer develop-
ment control the activation of speciﬁc intracellular signalling
pathways, particularly PI3K/Akt, EGFR, HER2/neu, PKC1,
Src, and Ras, that are activated in more than half of ovarian
neoplasms and thus could represent future targets for new
anticancer agents.
In particular, EGFR and HER2/neu activate signaling
pathways (PI3K/Akt and ERK1/2 MAP kinase), leading to
diﬀerent cellular processes involved in tumor development,
suchascelldivisionandmigration,adhesion,diﬀerentiation,
and apoptosis [58]. Aberrant EGFR and HER2 expression
was reported in ovarian carcinomas [59]. This evidence
prompted the development of several strategies to target
EGFR and HER2: monoclonal antibodies directed against
the extracellular domain of the receptors or small molecules
targeting the intracellular tyrosine kinase domains (tyrosine
kinaseinhibitors(TKIs))areinvariousstagesofclinicaltrials
for ovarian cancer [60].
However, the molecular pathways underlying ovarian
cancer progression are still poorly understood and currently
the signaling pathway research identiﬁed promising novel
candidates for cancer treatment and thus much eﬀort has
been made to establish signal transduction as target for
therapy.
One of the major challenges for ovarian cancer clinical
outcome is the occurrence of metastasis. Ovarian cancer
spreads by direct seeding of cells into the peritoneal cavity
wheretheyformcancernodules,bylymphaticdissemination
tothe pelvis, or, less frequently,by hematologicaldiﬀusion to
the parenchyma of the liver or lung. Ovarian cancer metas-
tasis in the peritoneal cavity is not limited by anatomical
barriers, thus peritoneal metastatic lesions can easily implant
and give rise to ascitic tumor cells growing in plasma-derived
exudate. Both tumor size and accumulation of ascites are
inversely associated with survival [61].
Some of the EOC clinical features (failure to early
disease detection, resistance to chemotherapy, high rate of
recurrence) have been recently ascribed to the presence, as in
other solid human cancer types, of cancer stem cells (CSCs)
a rare cell subpopulation that maintain their tumorigenic
potential after cytotoxic therapy.
These tumor characteristics well ﬁt with the known
properties of CSC such as quiescence and elevated multidrug
resistance activity, leading to insensitivity to cytotoxic drugs,
and multipotency, resulting in diversity in histological
phenotype associated with ovarian cancer. A large number
of studies on tumor-initiating stem cells in hematological
and solid cancers have been published (for review see [62]),
although very few reports addressed the role of CSCs in
EOC. Stem and progenitor-like cells able of self-renewal,
pluripotency, diﬀe r e n t i a t i o ni nv i t r oa n di nv i v oh a v eb e e n
recently isolated from human epithelial ovarian cancers
[63]. It was also hypothesized that putative ovarian CSC
possesses an altered mitochondrial phenotype associated to
its evolution towards tumorigenesis. Few studies showed
the isolation of putative mouse ovarian CSC endowed with
clonogenic, tumorigenic activity in vivo, and enhanced
chemo-resistance in vitro [64, 65]. Another recent evidence,
supporting the role of CSC in EOC, was reported by Alvero
et al., describing that these cells have a distinctive genetic
proﬁle that confers them the capacity to form ascites and
solid tumors, display chemoresistance, and promote tumor
recurrence [66].
A further development of this research area is required
to unequivocally deﬁne the contribution of CSC to human
ovarian cancer development, and the signaling pathways
involved. Importantly, these ﬁndings could lead to new
therapeutic strategies to speciﬁcally target ovarian CSCs.
Moreover, this knowledge is essential to understand the
mechanisms underlying the risk factors for this important
disease and is crucial for the development of eﬀective
screening protocols aimed at its early detection. On these
bases, an improved understanding of the molecular biology
of ovarian cancer may lead to the discovery of novel
molecular targets for the treatment of ovarian cancer.
5. Chemokines inOvarianCancer
One novel and, possibly, extremely relevant signaling path-
way in ovarian cancer development, growth, and diﬀusion
is represented by the chemokine system. In EOC there is
now evidence for a complex chemokine network regulatingJournal of Oncology 7
autocrine/paracrine mechanisms, relevant for the biology
of both normal and malignant ovarian cells [67, 68]. As
outlined before, chemokines expressed in cells of tumor
microenvironment can aﬀect the type and the degree of the
immune inﬁltrate in the tumor. Among chemokines, the CC
subfamily,andparticularlyCCL2,isthemostoftenexpressed
in ovarian cancer histotypes [69] being particularly involved
in macrophage recruitment. Negus et al. [70] reported the
expression of CCL2 and CCL5 in epithelial ovarian cancer
cellsanddemonstratedtherelationshipbetweenthepresence
of CCL2 with the extent of immune cell inﬁltration. More
recently, the analysis of ovarian cancer ascitic ﬂuid and ascite
cells allowed the identiﬁcation of the expression of CCL2,-
3,-4,-5,-8, and -22, altogether with their receptors (namely,
CCR1, -2a,-2b, -3,-4,-5, and-8), at mRNA and protein level
[71]. However, a deﬁnite correlation between this expression
pattern and the total cell counts in ascites or the stage of
the disease still has not been completely reached. Indeed,
tumors appear to utilize the same molecular mechanisms
used by normal immune system to eliminate malignant
cells. Concerning this topic, the inﬂuence of chemokines in
the antitumor immune response has been described in a
study that strongly supports the view that tumor-associated
regulatory T cells (mediators of the immune tolerance by
suppressing autoreactive T cells directed towards tumor
antigens) impair the function of T eﬀector cells in tumor-
bearing patients [72]. Tumor tissue and ascites from patients
with ovarian cancer contain high levels of cells with the
hallmarks of regulatory T cells. These cells migrate into
the tumor microenvironment in a process mediated by the
chemokine CCL22 and are capable of suppressing antitumor
responses. This speciﬁc recruitment of regulatory T cells
represents a mechanism by which tumors may develop
immune advantages and, as a consequence, the suggested
inhibition of regulatory T cell migration or function using
antibodies against CCL22, may represent a novel antitumor
approach.
One of the main features of all solid tumors is their
dependence on neovascularization. Cancer cells recruit
endothelial cells through the activity of several chemokines,
cytokines, and growth factors. Angiogenesis is also critical
for ascites development and metastasis in ovarian cancer.
The role of chemokines in tumor angiogenesis is well
known, and this process is mainly controlled by chemokines
of the CXC family in a negative (angiostatic chemokines,
ELR-) or positive manner (angiogenic, ELR+) [73]. In
particular, CXCL8/IL-8 and CXCL1-3/GROα, β and γ,a n d
CXCL5/ENA-78 induce angiogenesis through the activation
of direct mechanisms on endothelial cells [74]. In ovar-
ian cancer, the existence of a direct relationship between
the expression of angiogenic molecules and the patho-
logical behavior of ﬁve diﬀerent human ovarian cancers,
xenografted in the peritoneal cavity of nude mice, was
reported, demonstrating that the expression of CXCL8/IL-
8 was associated with neovascularization and inversely
correlated to survival [75].
Most chemokines sustain cancer cell proliferation and
survival acting as autocrine factors, as reported for CXCL8 in
Hey-A8 human ovarian cancer cells line blocked by speciﬁc
neutralizing antibodies. Moreover, CXCL8-overexpressing
cells when xenotransplanted in mice display an increased
cell growth, microvessel density, and the tumorigenic rate
[20]. Similarly, in vitro, IL-6 and CXCL8/IL-8 accelerate the
proliferation rate of several EOC cell lines [76].
The metastatic spread of tumors is controlled by the
microenvironment of the metastatic organ that supports
the homing and the growth of the tumor cells. Several
observations indicate that the tumor microenvironment at
metastatic sites is enriched with chemokines and that tumor
cells, expressing the cognate receptors, migrate and adhere in
response to the chemokines promoting metastasis formation
at these speciﬁc target organs.
In this respect, a very extensive research was performed
on CXCL12/CXCR4 ligand/receptor pair in breast cancer,
showing high expression of CXCL12 in target metastatic
organs of breast tumor cells, and the expression of CXCR4
in tumor cells [77].
An important role for the CXCL12/CXCR4 axis in
ovarian tumor metastasis was also identiﬁed and a cor-
relation between the activity of this chemokine system
and an enhanced intraperitoneal dissemination of EOC
was described [78] (see below). However, it is clear that
CXCL12 does not act by itself, and other pairs of chemokines
of diﬀerent families and their respective receptors are
involved in metastasization. In EOC ascitic ﬂuid and
blood of patients the reduction of migration responses
of monocyte/macrophages expressing several chemokine
receptors(CCR1,CCR5,andCXCR4)producedinthetumor
microenvironment, has been described [79]. In particular,
the role of CCL11/eotaxin-1 in proliferation and invasion
of ovarian cancer cells was analyzed. EOC overexpressed
CCR2, 3, and 5, the cognate receptors of CCL11, with a
strong positive correlation between tumor grade and the
levels of each of these receptors. Interestingly, the inhibition
of CXCL11 activity by neutralizing antibodies signiﬁcantly
increases cis-platinum response in ovarian carcinoma cells
[80].
6. CXCL12/CXCR4ExpressioninOvarian
Cancer and ItsRole inTumor Cell
Proliferation andMetastases
In2001and2002Scottonetal.investigated,fortheﬁrsttime,
the possible role of CXCL12 in ovarian cancer [25, 81]. In
particular the expression of chemokines and their receptors
was reported in ten primary ovarian tumors, six cell lines,
and twenty ovarian cancer ascites. From these studies it
was shown that CXCR4 was the only chemokine receptor
expressed in these cells. Its expression was evidenced not
only in tumor cells but also in mononuclear and endothelial
cells within the tumor tissues; whereas endothelial cells in
tissuesadjacenttothetumorswerenegative.CXCR4wasalso
expressedinalmostallthecellsderivedfromascites,andhigh
concentrations of CXCL12 were detected in all ascitic ﬂuids
analyzed.
Interestingly, CXCR4 and CXCL12 are not involved
in the biology of normal ovarian epithelium since their8 Journal of Oncology
expression was not detected in normal ovarian tissues and
in healthy women with family history of ovarian cancer.
In contrast, papillary serous and endometrioid ovarian
tumors display a high expression of CXCL12. Low-grade
ovarian cancers were reported to have a diﬀerential pattern
of expression, with benign mucinous tumors negative but
serous benign positive for the expression of this chemokine
[25].
Subsequently,CXCR4andCXCL12expressioninovarian
cancer have been conﬁrmed by other studies [78, 82, 83].
More recent detailed analysis showed the expression
of CXCR4 and CXCL12 also in normal ovary, but their
localization was conﬁned to the follicular cells and it
was not detected in normal epithelium [82]. However, in
consideration that 91% and 59% of ovarian cancers express
CXCL12 and CXCR4, respectively, it was proposed that an
overexpression of this chemokine system was present in
ovarian malignant cells. In addition, the CXCR4/CXCL12
expression was associated with unfavorable prognosis with
signiﬁcantly reduced median disease progression-free sur-
vival [82]. Similarly, Kajiyama et al. [78] demonstrated that
in patients whose tumors were positive for the expression of
CXCR4, the overall survival was signiﬁcantly worse than in
patients negative for CXCR4 expression. Moreover, the level
of CXCL12 in the ascites was directly related to the stages of
disease.
Thus,evenifthepublishedstudiesindividuallyexamined
a small number of ovarian cancers, all these results agree
that CXCL12/CXCR4 axis may be closely associated with the
development of peritoneal metastasis and the prognosis of
patients with epithelial ovarian carcinoma (EOC).
In vitro studies directly demonstrated that, in the
presence of CXCL12, CXCR4 controls both ovarian cancer
cell proliferation and migration, through the activation of
the ERK1/2 and Akt pathway [40]. In addition, it was
also demonstrated that CXCL12 eﬀects on ovarian cancer
cell lines are mediated by EGFR transactivation through
a mechanism involving the activity of cytosolic tyrosine
kinases, belonging to the c-Src family [84].
Inhibition of CXCR4 activity reduces intraperitoneal
disseminationofovariancancerxenografts.Invitro,CXCL12
induces cell migration and invasion of the IGROV ovar-
ian cancer cell line. Human peritoneal mesothelial cells
(HPMCs), lining the peritoneal cavity, bind to EOC in the
initial step of peritoneal metastasis. CXCL12 is predomi-
nantly expressed in HPMCs rather than in EOC cells, while
CXCR4 was found in both EOC and HPMCs, thus creating
an extracellular chemotactic milieu for EOC migration.
Moreover, coculture experiments, using HPMCs and EOC,
showed a strong increase in CXCL12 release, suggesting
that some tumor-derived factors upregulate CXCL12 levels
in ascites. TGFβ1 may be one of these factors increasing
CXCL12 production. AMD3100, a potent CXCR4 antago-
nist, reduced the formation of peritoneal metastasis in an in
vivo experimental model, even if no signiﬁcant diﬀerences in
survival were observed between mice treated with AMD3100
and control mice [78]. Clinical trials should become feasible
with the development of novel orally available CXCR4
inhibitors.
Ovarian cancer metastasizes preferentially to local lymph
nodes and peritoneum and, in contrast with breast cancer,
only rarely in other organs such as liver, lung, and bones.
Ovarian and breast cancers share the overexpression
of HER2/neu, a member of the EGFR family. HER2/neu
increases the metastatic potential in murine and human cell
lines and induces mammary tumors and lung metastases in
transgenic animal models [85]. CXCR4 plays an important
role in targeting the metastasis of breast cancer. Malignant
breast cancer cells express CXCR4, invade the extracellular
matrix, and circulate in the blood and lymphatic vessels
attracted by CXCL12 that is abundantly released by target
metastatic organs. Recently, it has been demonstrated that
the overexpression of HER2/neu in breast cancer enhances
the metastatic potential through the upregulation of CXCR4,
providing a link between CXCR4 and HER2/neu in tumor
progression and metastasis [86].
A similar study was performed in a cohort of 148 ovarian
tumorsamplesbyimmunohistochemistryontissuemicroar-
rays [87]. HER2/neu overexpression was found in a quarter
ofmalignanttumorsandassociatedwithsigniﬁcantlyshorter
overall survival, in agreement with the majority of publica-
tions. However, HER2/neu positive patients did not show a
higherexpressionofcytoplasmicCXCR4staining,whichwas
positive in over half of the cases and closely correlated with
CXCL12 expression [87]. The lack of inﬂuence of CXCR4
in ovarian cancer could reﬂect the peculiar characteristics
of the metastatic process in ovarian cancer as compared
to other cancers such as colon [88], non-small-cell lung
cancer [89], gliomas [90], malignant melanomas [28], oral
squamouscarcinoma[91],andadultacutemyeloidleukemia
[92]. In these types of cancer, distant metastasis, favored by
CXCL12 expression on target organs, signiﬁcantly inﬂuences
the survival, while in ovarian cancer the recurrence in the
pelvis and in the peritoneum is the main cause for death.
Nevertheless, it needs to take in account that, in this study,
CXCR4 and HER2/neu expression was evaluated in paraﬃn-
embedded tissues blocks and their histology and grading
was related with survival of patients, without analysis of the
metastatic sites.
Thus, the presence of high level of CXCL12 in the ascitic
ﬂuids as well as the inhibition of intraperitoneal dissemi-
nation of ovarian cancer xenografts by CXCR4 antagonist
suggests that CXCR4/CXCL12 axis may be important in the
invasion of ovarian cancer cells and further studies will be
necessary to better deepen this important question.
The published studies dealing with the expression of
CXCL12 and CXCR4 in human ovarian cancer cell lines,
tumor biopsies and ascite cells are summarized in Tables 1
and 2,r e s p e c t i v e l y .
Interestingly, also in other gynecological cancers, such
as cervical and endometrial carcinomas, chemokines were
reported to have a pathogenic role.
Most of the early studies on the role of CXCR4 in cervical
cancer were performed using the HeLa cell line (cervical
adenocarcinoma-derived cell), the ﬁrst immortalized cell
line developed for research purposes [95, 96]. CXCL12
stimulation of HeLa cells induces increase of intracellular
calcium concentrations, activation of ERK1/2 MAP kinase,Journal of Oncology 9
Table 1: CXCR4 and CXCL12 expression in human ovarian cancer cell lines.
Ovarian cancer cell lines CXCR4 expression CXCL12 expression References
Protein mRNA Protein mRNA
IGROV, CAOV-3, PEO1, PEO14 X X X X [81]
OVCAR-3, SKOV-3 Not detected Not detected Not detected Not detected [81]
IGROV, CAOV-3 X X [25]
OC 314, OC 315, OC 316 X X X [40]
SKOV-3, RMG-I, NOS-2, KOC-7C, X X X [78]
ES2, NOS-4 X [78]
B G - 1 XXXX [ 93, 94]
Table 2: CXCR4 and CXCL12 expression in human ovarian carcinomas and tumor ascite cells.
Ovarian carcinoma CXCR4 expression CXCL12 expression References
Solid tumors (positive/total, %) Protein mRNA Protein mRNA
8/10, 80% X X X X [81]
19/20, 95% X X [81]
16/18, 88% X X [25]
26/44, 60% X [82]
40/44, 91% X [82]
27/30 (metastatic), 91% X [82]
23/30 (metastatic), 77% X [82]
12/12, 100% X X X X [83]
119/128, 93% X [87]
128/128, 100% X [87]
16/36, 44% X [78]
Ascites (positive/total, %)
63/63, 100% X [81]
26/26, 100% X [78]
PI3K-Akt and Jak-STAT pathways; all these signals cooperate
in cell migration and spreading. Studies on human cervical
carcinoma (HCC) demonstrated high expression of CXCR4
inHCC-derivedcelllinesandintissuesections,whilenormal
cervical epithelium was negative [97]. CXCL12 binding to
CXCR4 induces cell movement, cytoskeleton reorganization,
and gene activation, synergizing with hepatocyte growth
factor. In fact, metastasization of cervical adenocarcinoma
or squamous cell carcinomas is more frequent in tumors
expressing high levels of CXCR4 than tumors that express
either low levels or are negative for CXCR4 [98, 99]. Also
CCR7 levels in cervical adenocarcinoma/squamous cells are
associated with invasion of lymph nodes as well as tumor
cell proliferation and survival. CXCR4 and CCR7 expression
is signiﬁcantly higher in patients with larger tumor size,
deepstromalinvasion,lymph-vascularspaceinvolvement,or
lymph node metastasis [100]. As far as endometrial cancer,
studies on CXCR4 and CXCL12 expression revealed that
CXCR4 is overexpressed in endometrial cancers as compared
with normal tissues, whereas CXCL12 was overexpressed in
normal mucosa. In addition, in vivo cell migration may
be contrasted by CXCR4 neutralizing monoclonal antibody
that reduces size and number of the metastasis in all target
organs (peritoneum, lung, liver) [101]. However, a diﬀerent
study shows that CXCR4 expression was inversely related to
tumor grade and patient outcome [100]. On the contrary, no
diﬀerencebetweencancerandnormaltissueswasreportedas
far as CXCR7 expression [101].
7. CXCR4/CXCL12and PrimordialGerm
Cells Development
Ovarian germ cell tumors (OGCTs) account for about 20%
of all ovarian neoplasms and constitute the second largest
groupofovariancancermainlyaﬀectingyoungwomen(58%
of all ovarian tumors in women younger than the age 20
years). They histogenetically derive from primordial germ
cells and diﬀer with regard to clinical presentation, tumor
biology, and histology. OGCTs include both benign (pre-
dominantly) and malignant (MOGCT) subtypes. MOGCTs
are rare but aggressive and very curable tumors, accounting
for approximately 1-2% of all ovarian malignancies [102].
In most organisms primordial germ cells(PGCs) migrate
through developing embryo to reach the location where the
gonad develop. In this process somatic cells of the gonads
support the proper development of germ cells, the lineage
that gives rise to sperm and eggs.10 Journal of Oncology
In mice lacking CXCL12, the colonization of gonads
by PGCs is impaired [103]. CXCR4 is expressed in mouse
germ cells; whereas expression of its ligand is high in the
genital, the target of the migrating cells. In fact, CXCL12
is essential for homing of PGCs into genital ridges but
is not required for direct migration through tissues of
embryos [104, 105]. Diﬀerent studies demonstrated that
in mouse germ cell migration and survival requires the
CXCL12/CXCR4 interaction [106, 107].
Recently, it was reported that also the other CXCL12
receptor, CXCR7, takes an active part in the migration
of PGCs; knockdown of CXCR7 gene results in impaired
polarity and aberrant migration of PGCs [108]. Unlike
CXCR4, CXCR7 function was found to be required in
tissues surrounding the migrating cells (where it is found
primarily in intracellular structures) rather than in PGCs.
It was suggested that the key role of CXCR7 is to bind
and internalize CXCL12 thereby controlling the level of the
diﬀusible chemokine in the extracellular space [108]. Thus,
CXCR7 may act as a high-aﬃnity decoy receptor to facilitate
the migration of PGCs by shaping the distribution of the
chemokine in the environment [109].
CXCR4 and CXCL12 control cell migration in several
normal and pathological conditions [103–105, 108, 109].
In neonatal mice CXCL12/CXCR4 signalling contributes to
maintain the size and longevity of the primordial follicle
pool [106]. CXCL12/SDF1α and β (but not CXCL12/SDF1γ)
transcript variants were identiﬁed in cultured neonatal
and adult ovary by microarray analysis and RT-PCR. In
neonatal tissues both CXCL12 and CXCR4 display similar
expression pattern. They are detected in primordial and
primary/secondary oocytes with lower level of staining in
the interstitial tissues and granulosa cells. The primordial
oocytes are essentially “resting” cells with limited metabolic
capability suggesting that the presence of CXCR4/CXCL12
may be with index of an essential role for this chemokin
system within the follicle [106].
Recently it was proposed an innovative hypothesis con-
cerning the cell type by which ovarian epithelial tumors may
rise [110]. In fact, it was widely accepted that the origin of
epithelial ovarian tumors derives from the mesothelial cell
layer lining the ovary surface (ovarian coelomic epithelium).
However, it was observed that ovarian epithelial neoplasms
are remarkably similar to epithelial cells from extra-ovarian
sites in the female reproductive tract. The three most
common subtypes of these tumors, referred as serous,
endometrioid, and mucinous are morphologically identical
to carcinomas of the fallopian tube, endometrium, and
endocervix, respectively. It has been suggested that ovarian
epithelialcellscouldarisefromtissuesthatareembryological
derived from the Mullerian ducts.
In other types of cancer the physiological role of
CXCR4/CXCL12, carried out during the embryonic devel-
opment, is turned in the ability to inﬂuence cell migration
and spreading in cancer. Thus, studying CXCR4/CXCL12
function in epithelial ovarian cancer, the choice of an incor-
rect cell controls could bring wrong conclusions. It could
be possible that a deregulated CXCR4/CXCR7/CXCL12 axis
could be already evident in early stage of illness.
8.CXCR4as aPotentialTherapeutic Target
All the data previously discussed provide the rationale for
targeting CXCR4 in cancer. In particular, this notion is
further supported by the diﬀerent mechanisms resulting
from CXCR4 inhibition: (a) the reversal of stromal cell inter-
actions responsible of tumor cell survival; (b) the blockade
of proangiogenic activity of CXCL12 and the reduction of
the dissemination and migration ability of tumor cells; (c)
the blockade of tumor growth through autocrine/paracrine
signaling mediated by CXCL12/CXCR4 interaction; (d) the
mobilization of tumor cells from tissues to increase their
sensitivity to conventional chemoterapeutic agents.
On these premises, several molecules able to antago-
nize CXCR4 activity in response to CXCL12 have been
identiﬁed. To date four types of CXCR4 inhibitors have
been described: (1) peptide-based antagonists, (2) nonpep-
tidic antagonists; (3) neutralizing antibodies for CXCR4;
(4) modiﬁed CXCL12 peptides, endowed of antagonistic
activity.
The ﬁrst small peptide antagonists of CXCR4 (named
T22, T134, and T140) [111, 112] were discovered screening
compounds with potential anti-HIV-1 activity (CXCR4 acts
also as coreceptor in T-cell line tropic HIV infection [95,
96]). In particular T22 blocks CXCR4 activity by binding the
receptor region involved in HIV-1 entry into the cell. T140,
the most active antagonist [113], is a 14-residues peptide
with the main limitation in the low stability in serum. Thus,
this shortcome was overcome by modiﬁed structural analogs
(T14003 and TC14012) [114]. Recently, T140 synthesize
as cyclic peptide (FC131) [115], and a new antagonist
(named POL3026) [116], with better pharmacokinetic prop-
erties and potent CXCR4 antagonist activity, have been
described. In cancer, T140 eﬃcacy to block CXCR4 has been
reported in diﬀerent tumor models in vivo and in vitro,
including leukemia [117], breast [118] and lung cancers
[119], and malignant melanoma [120]. T140 and TN14003
are currently in clinical development for B-cell homing
[117].
Among nonpeptidic small molecules, cyclams and bicy-
clamssuchasAMD3100areendowedofCXCR4antagonistic
properties [121] and weak partial agonist activity [122–124].
Antitumor eﬃcacy of AMD3100 was demonstrated in
breast cancer where it blocks CXCL12-induced HER2/neu
activation in vitro [125] and inhibits tumor growth in vivo
[126]. Its antineoplastic activity has been also demonstrated
in pancreatic cancer cells, colorectal and glioblastoma tumor
xenografts [127–129]. Moreover, playing CXCR4 a key role
in cross-talk between leukemia cells and their microenviron-
ment, the potential use of this drug in hematological cancer
has been widely studied and it is currently used in clinics for
the mobilization of hematopoietic stem cells [130, 131].
Indeed, in hematological malignancies, tumor cells use
CXCR4 for dissemination and progression of the disease,
because interactions of CXCR4 with its ligand are critical
for hematopoietic cells traﬃcking and homing to lym-
phatic tissues [132]. Stromal cells within bone marrow
microenvironment constitutively secrete CXCL12 and the
activation of CXCR4 induces leukemia cell migration toJournal of Oncology 11
the marrow microenvironment, providing growth and drug
resistance signals. AMD3100 is able to mobilize leukemia
cells from their stromal microenvironment and inhibits
adhesive tumor-stroma interactions, thus making leukemia
cells accessible to conventional drugs [133].
AMD3100hasalsobeenusedasagentthatdisruptsinter-
action with the bone marrow microenvironment in multiple
myeloma cells [134] and in between mantle cell lymphoma
cells [135]. Therefore, targeting the CXCR4/CXCL12 axis
is attractive therapeutic approach in leukemia patients. It
was shown that in leukemia cells, several growth and sur-
vival factors from the tumor microenvironment, including
CXCR4 activation, induce PI3K activation. Therefore, the
activity of isoform-selective PI3K inhibitors was investigated
to indirectly block CXCL12/CXCR4 signals in chronic cell
leukemia leading migration, stromal cell interactions, and
stromal cell-mediated drug resistance [136].
AMD3100 was successfully used in both in vitro and in
vivo experiments carried out in ovarian cancer cells [25].
Antibodies against CXCR4 have been reported to aﬀect
HIV-1 infection and cancer cell migration [137]. The limit-
ing point for monoclonal antibody therapeutic development
is due to the high frequency of heterogeneous conformation
ofCXCR4andposttranslationalmodiﬁcationthatreducethe
antibody speciﬁcity and function [138].
Antichemokine activity was also identiﬁed in some
natural compounds. Soybean and cruciferous vegetables
have been implicated in the protection against spontaneous
and carcinogen-induced cancers although the mechanisms
forthisanticarcinogenicityarenotfullyelucidated.Epidemi-
ologic studies in Asian women indicate that consumption of
a traditional diet high in soy confers signiﬁcant protection
against breast cancer [139].
3,3-Diindolylmethane (DIM) and genistein, dietary
phytoestrogens, belonging to isoﬂavone class of ﬂavonoids,
have anticarcinogenic activities [140]. Recently, Hsu et
al. demonstrated that DIM inhibits the chemotactic and
invasivepotentialofbreastandovariancancercellsespecially
through an estrogen-independent mechanism, reducing the
chemotaxis towards CXCL12. In addition, downregulation
of CXCR4 and CXCL12 and inhibition of chemotaxis and
chemoinvasion in breast and ovarian cancer cells toward
CXCL12 are among of the biological eﬀects of genistein
[93] likely through the inhibition of the estrogen dependent
CXCL12 mRNA synthesis.
9. Conclusions
One of the topics emerging from this review is that
ovarian cancer growth and metastasis can be controlled by
immunomodulatory and chemotactic chemokines. Indeed,
chemokine/chemokine receptor systems attract increasing
attention as anticancer strategies due to their direct involve-
ment in almost every aspect of tumorigenesis. Thus, further
b i o l o g ya n dp h a r m a c o l o g ys t u d i e sh a v et ob ed e v e l o p e dt o
fully address the chemokinergic system as an ideal target for
the inhibition of tumor proliferation, angiogenesis, invasion,
and metastasization.
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